https://www.nasdaq.com/press-release/ampio-pharmaceuticals-ceo-mike-martino-issues-letter-to-stockholders-2021-12-16
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-announces-pricing-of-%2422.5-million-registered-direct-offering
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-host-business-update-call-with-chairman-and-ceo-mike-martino
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-announces-shareholder-business-update-call-with-its-ceo
https://www.nasdaq.com/press-release/board-member-michael-martino-to-become-interim-chairman-and-ceo-of-ampio
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-announces-third-quarter-2021-financial-results-and
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-report-fiscal-2021-third-quarter-financial-results-and
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-strengthens-management-team-and-board-of-directors-2021-10-13
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-receives-approval-from-the-drugs-controller-general-of-india
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-announces-top-line-results-from-ap-013-phase-iii-study-of
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-announces-important-new-research-manuscript-on-anti
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-reminds-stockholders-to-vote-shares-in-advance-of-2021-annual
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2021-08
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-announces-second-quarter-2021-financial-results-and
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-the-american-college-of-toxicology-42nd-annual
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-the-14th-international-congress-on-systemic-lupus
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-aspen-lung-conference-2021-07-27
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-report-fiscal-2021-second-quarter-financial-results-and
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-announces-patient-randomization-and-dosing-in-ap-019-phase-ii
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-join-the-russell-2000r-index-and-russell-3000r-index
https://www.nasdaq.com/press-release/ampio-provides-update-on-osteoarthritis-of-the-knee-oak-program-reiterates-compelling
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-receives-approval-to-expand-enrollment-of-its-ap-019-phase-ii
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-the-2021-international-society-for-pharmaceutical
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-participate-in-the-alliance-global-partners-virtual-summer
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-poster-at-the-international-society-for-aerosols-in
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-receives-investigational-review-board-approval-for-its-phase-i
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-provides-updates-on-clinical-programs-for-ampiontm-in
https://www.nasdaq.com/press-release/ampiontm-reduces-all-cause-mortality-in-covid-19-respiratory-distress-by-nearly-80
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-report-fiscal-2021-first-quarter-financial-results-and
https://www.nasdaq.com/press-release/research-shows-ampiontm-gene-regulation-mimics-the-anti-inflammatory-effects-of
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-study-shows-ampion-inhibits-a-key-inflammatory-pathway-in-covid
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-the-international-society-for-aerosols-in
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-benzinga-biotech-small-cap-conference-2021-03-19
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-details-early-positive-results-for-inhaled-ampion-in-covid-19
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-participate-in-the-33rd-annual-virtual-roth-conference-on
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-reports-fourth-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-to-present-at-the-h.c.-wainwright-global-life-sciences
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-report-annual-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/ampio-brings-new-hospitals-online-in-trial-for-inhalation-treatment-of-covid-19-with
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-present-at-upcoming-investor-conference-2021-02-16
https://www.nasdaq.com/press-release/ampio-announces-early-positive-data-in-phase-1-trial-of-inhaled-ampion-in-covid-19
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-ongoing-phase-i-clinical-trial-for-inhalation-treatment-of
https://www.nasdaq.com/press-release/ampio-provides-update-on-clinical-trials-for-ampiontm-treatment-of-covid-19-patients
https://www.nasdaq.com/press-release/ampio-receives-feedback-from-the-fda-on-ampios-proposed-modifications-to-the-special
https://www.nasdaq.com/press-release/ampion-demonstrates-safety-in-covid-19-patients-and-initiates-global-clinical-trial
https://www.nasdaq.com/press-release/ampio-enters-into-collaborative-research-agreements-to-explore-additional-clinical
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-host-its-annual-meeting-on-december-12-2020-2020-12-08
https://www.nasdaq.com/press-release/ampios-phase-i-study-for-inhaled-ampion-advances-to-completing-enrollment-of-covid-19
https://www.nasdaq.com/press-release/ampio-updates-regulatory-and-clinical-trial-events-2020-11-25
https://www.nasdaq.com/press-release/ampios-phase-i-study-for-inhaled-ampion-advances-to-3rd-group-of-covid-19-patients
https://www.nasdaq.com/press-release/ampios-phase-i-study-for-inhaled-ampion-advances-to-2nd-group-of-covid-19-patients
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-provides-business-update-and-reports-third-quarter-2020
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-host-conference-call-on-november-5th-2020-11-02
https://www.nasdaq.com/press-release/ampio-begins-phase-1-clinical-trial-of-inhaled-ampion-for-covid-19-patients-with
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-present-at-the-roth-capital-healthcare-event-covid-19
https://www.nasdaq.com/press-release/ampio-presents-at-roth-capital-partners-2020-medtech-innovation-forum-focusing-on
https://www.nasdaq.com/press-release/ampio-publication-reports-beneficial-effects-of-ampion-on-important-transcription
https://www.nasdaq.com/press-release/fda-grants-ind-and-approves-clinical-trial-protocol-of-inhaled-ampion-for-covid-19
https://www.nasdaq.com/press-release/ampion-phase-i-covid-19-patient-trial-results-featured-on-fox-news-video-2020-09-14
https://www.nasdaq.com/press-release/ampio-reports-positive-results-for-ampion-treatment-in-covid-19-patients-2020-09-09
https://www.nasdaq.com/press-release/ampio-announces-enrollment-completion-for-intravenous-iv-covid-19-clinical-trial
https://www.nasdaq.com/press-release/ampio-provides-update-on-covid-19-clinical-trial-activities-2020-08-19
https://www.nasdaq.com/press-release/ampio-starts-patient-enrollment-in-its-ampion-covid-19-program-2020-07-23
https://www.nasdaq.com/press-release/ampio-reports-a-publication-on-the-potential-benefits-of-ampion-for-treatment-of-a
https://www.nasdaq.com/press-release/ampio-to-start-first-clinical-trial-in-covid-19-program-2020-06-19
https://www.nasdaq.com/press-release/ampio-provides-update-on-covid-19-program-2020-05-22
https://www.nasdaq.com/press-release/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized
https://www.nasdaq.com/press-release/ampio-pharmaceuticals-application-to-the-fda-for-a-clinical-study-of-ampiontm-to
https://www.nasdaq.com/press-release/ampio-suspends-patient-enrollment-in-its-phase-3-study-of-ampion-for-severe
https://www.nasdaq.com/press-release/ampio-is-preparing-an-expanded-access-fda-protocol-to-study-nebulized-ampion-as-a
https://www.nasdaq.com/press-release/ampio-provides-corporate-update-2020-02-21
